Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage oncology company based in Los Angeles, announced that its President and Chief Scientific Officer, Neil Bhowmick, will present and moderate a discussion at the 24th Annual Discovery on Target Drug Discovery Conference. The event, scheduled for September 28 to October 1 in Boston, brings together experts from across the pharmaceutical and biotechnology industries to discuss emerging trends and breakthroughs in drug discovery.
Bhowmick will moderate a breakout session on September 30 titled “Winning the Race against Cancer Therapy Resistance.” This session will focus on Kairos Pharma’s strategy of targeting cancer drug resistance to extend the efficacy of previously effective drug candidates. The company’s approach is rooted in structural biology, aiming to overcome mechanisms that allow cancer cells to evade standard therapies and suppress immune responses.
In addition to moderating, Bhowmick will deliver an oral plenary presentation on September 30 at 2:35 p.m. Eastern Time on KROS-101, a drug candidate targeting solid tumors. The presentation will highlight KROS-101’s mechanism of action, which involves targeting GITR (Glucocorticoid-Induced TNF Receptor) to increase T-cell function and expand effector T-cells with anti-tumor activity. This novel approach could potentially enhance the body’s immune response against cancer, offering a new avenue for treatment.
The importance of this announcement lies in its potential to address a critical challenge in oncology: drug resistance. Many cancer therapies eventually fail because tumors develop resistance, leading to disease relapse. Kairos Pharma’s focus on reversing resistance and restoring the effectiveness of standard therapies could significantly improve patient outcomes. The company’s lead candidate, ENV-105, an antibody targeting CD105—a protein identified as a key driver of resistance and relapse—aims to reverse drug resistance across multiple cancer types.
By presenting at a prestigious conference like Discovery on Target, Kairos Pharma gains visibility among key stakeholders, including potential partners, investors, and researchers. The event provides a platform to showcase its innovative research and validate its scientific approach. This exposure could accelerate partnerships and funding opportunities, ultimately advancing its pipeline toward clinical trials and commercialization.
For investors, the announcement signals progress in Kairos Pharma’s research and development efforts. The company’s participation in such a forum underscores its commitment to addressing unmet needs in cancer treatment. As Kairos Pharma continues to develop its portfolio, including KROS-101 and ENV-105, it positions itself at the forefront of oncology therapeutics.
For more information about Kairos Pharma and its initiatives, visit its client page. The full press release can be accessed at https://nnw.fm/DoHxL. The latest news and updates relating to KAPA are available in the company’s newsroom at https://nnw.fm/KAPA.
NetworkNewsWire, a specialized communications platform, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. It delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit NetworkNewsWire. Please see full terms of use and disclaimers on the NetworkNewsWire website: https://www.NetworkNewsWire.com/Disclaimer.
